L3VLUP
ProSign in

CRSP · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CRSPGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CRSP
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterCRSPGILD
Q3 20204 holders, $763m25 holders, $14.2bn
Q4 20209 holders, $2.0bn27 holders, $13.4bn
Q1 20214 holders, $1.3bn24 holders, $14.5bn
Q2 20214 holders, $1.5bn18 holders, $14.9bn
Q3 20214 holders, $903m20 holders, $16.4bn
Q4 20214 holders, $781m20 holders, $16.8bn
Q1 20226 holders, $696m28 holders, $13.2bn
Q2 20226 holders, $799m26 holders, $13.6bn
Q3 20225 holders, $603m24 holders, $13.3bn
Q4 20226 holders, $369m32 holders, $21.1bn
Q1 20234 holders, $380m27 holders, $21.8bn
Q2 20236 holders, $483m24 holders, $20.7bn
Q3 20234 holders, $354m24 holders, $20.0bn
Q4 20234 holders, $609m22 holders, $21.5bn
Q1 20244 holders, $595m30 holders, $20.3bn
Q2 20245 holders, $480m28 holders, $18.5bn
Q3 20244 holders, $403m29 holders, $24.2bn
Q4 20242 holders, $388m28 holders, $25.9bn
Q1 20253 holders, $414m33 holders, $32.0bn
Q2 20254 holders, $643m27 holders, $30.9bn
Q3 20254 holders, $748m23 holders, $29.4bn
Q4 20251 holders, $552m25 holders, $34.3bn
Q1 20264 holders, $840m25 holders, $38.5bn
Q2 20263 holders, $883m26 holders, $34.2bn
CRSP

Crispr Therapeutics AG

Holders
4
Reported value
$643m
Buyers
4
Sellers
0

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
27
Reported value
$30.9bn
Buyers
18
Sellers
10

Breadth +8 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2025

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only CRSP (3)

ARK Investment Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP

Only GILD (26)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →